SAN CLEMENTE, Calif.–(BUSINESS WIRE)–AtaCor Medical, Inc. (“AtaCor”) announced today that it will present initial findings from its first-in-human extravascular implantable cardioverter defibrillator (EV-ICD) study during the upcoming Stanford Biodesign New Arrhythmia Technologies Retreat. The presentation, leading up to the Heart Rhythm 2022 Scientific Congress in San Francisco, is scheduled for 9:50 a.m. on Thursday, April 28, 2022, in Palo Alto, CA.